Ecuador vs Guinea-Bissau: Average cost of multi drug-resistant tuberculosis treatment
Ecuador
1,121 constant 2022 US$
in 2024
Guinea-Bissau
1,120 constant 2022 US$
in 2024
Ecuador rank
42nd
Guinea-Bissau rank
43rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Ecuador
- Guinea-Bissau
How they compare
Ecuador currently reports 1,121 constant 2022 US$ against 1,120 constant 2022 US$ in Guinea-Bissau, a difference of 1 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Guinea-Bissau ahead.
Ecuador ranks 42nd and Guinea-Bissau ranks 43rd of 92 countries.
Across the 2 decades both report, Ecuador averaged higher in 1 and Guinea-Bissau in 1.
Head to head by decade
| Decade | Ecuador | Guinea-Bissau | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 754 constant 2022 US$ | 2,481 constant 2022 US$ | 1,727 constant 2022 US$ | Guinea-Bissau |
| 2020s | 1,440 constant 2022 US$ | 1,045 constant 2022 US$ | 394.4 constant 2022 US$ | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Ecuador or Guinea-Bissau?
- Ecuador, at 1,121 constant 2022 US$ against 1,120 constant 2022 US$ in Guinea-Bissau as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Ecuador and Guinea-Bissau?
- 1 constant 2022 US$, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Guinea-Bissau?
- 8 years are reported by both, from 2017 to 2024.
- How do Ecuador and Guinea-Bissau rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Ecuador ranks 42nd and Guinea-Bissau ranks 43rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.